文献速递乳腺癌

甲磺酸艾立布林对比长春瑞滨治疗局部复发或转移性乳腺癌女性的随机临床试验

Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.
PubMed 文献 · Eur J Cancer · 2019-03-29

这项III期开放标签随机多中心试验纳入530例既往接受过2-5线化疗(含蒽环类和紫杉类)的中国局部复发或转移性乳腺癌女性,1:1随机接受艾立布林或长春瑞滨治疗。艾立布林组无进展生存期(HR 0.80,95%CI 0.65-0.98,P=0.036)和客观缓解率(30.7% vs 16.9%,P<0.001)优于长春瑞滨组,两组中位无进展生存期均为2.8个月,总生存期无显著差异。

要点

  • 艾立布林组无进展生存期优于长春瑞滨组(HR 0.80,95%CI 0.65-0.98,P=0.036),但两组中位无进展生存期均为2.8个月。
  • 艾立布林组客观缓解率为30.7%,长春瑞滨组为16.9%(P<0.001)。
  • 导致治疗中止的治疗中出现的不良事件:艾立布林组7.2%,长春瑞滨组14.0%。

核心结论

  • 在既往接受过治疗的局部复发或转移性乳腺癌女性中,艾立布林相比长春瑞滨取得了统计学显著更优的无进展生存期和缓解率。
  • 艾立布林似乎比长春瑞滨耐受性更好,未观察到新的安全性信号。

研究设计与样本

  • III期开放标签、随机、平行组、多中心临床试验,于2013年9月26日至2015年5月19日入组。
  • 纳入既往接受过2-5线化疗(包括蒽环类和紫杉类)的局部复发或转移性乳腺癌患者。
  • 共530例女性1:1随机接受艾立布林(n=264)或长春瑞滨(n=266)。
  • 艾立布林1.4 mg/m2静脉给药,第1天和第8天,每21天;长春瑞滨25 mg/m2静脉给药,第1天、第8天和第15天,每21天。
  • 主要终点为无进展生存期,次要终点包括客观缓解率、缓解持续时间和总生存期。

主要发现

  • 艾立布林组相比长春瑞滨组无进展生存期改善(HR 0.80,95%CI 0.65-0.98,P=0.036),两组中位无进展生存期均为2.8个月。
  • 艾立布林组中位总生存期为13.4个月,长春瑞滨组为12.5个月(HR 1.03,95%CI 0.80-1.31,P=0.838)。
  • 艾立布林组客观缓解率为30.7%(95%CI 25.2%-36.6%),长春瑞滨组为16.9%(95%CI 12.6%-22.0%)(P<0.001)。
  • 导致治疗中止的治疗中出现的不良事件:艾立布林组7.2%,长春瑞滨组14.0%。

关键数值与推荐

  • 无进展生存期:艾立布林组相比长春瑞滨组HR 0.80(95%CI 0.65-0.98,P=0.036),两组中位无进展生存期均为2.8个月。
  • 总生存期:艾立布林组中位13.4个月 vs 长春瑞滨组中位12.5个月(HR 1.03,95%CI 0.80-1.31,P=0.838)。
  • 客观缓解率:艾立布林组30.7%(95%CI 25.2%-36.6%)vs 长春瑞滨组16.9%(95%CI 12.6%-22.0%)(P<0.001)。
  • 导致治疗中止的治疗中出现的不良事件发生率:艾立布林组7.2% vs 长春瑞滨组14.0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The objective of this study was to evaluate the efficacy and safety of eribulin monotherapy, relative to vinorelbine, in Chinese women with locally recurrent/metastatic breast cancer (MBC). METHODS: This phase III open-label, randomised, parallel-group, multicentre clinical trial enrolled patients with locally recurrent or MBC who had had 2-5 prior chemotherapy regimens, including an anthracycline and taxane) from September 26, 2013, to May 19, 2015. Women were randomised 1:1 to receive eribulin (1.4 mg/m2, intravenously, on day 1 and day 8) or vinorelbine (25 mg/m2, intravenously, on day 1, day 8 and day 15) every 21 days. The primary end-point was progression-free survival (PFS). Secondary end-points included objective response rate (ORR), duration of response and overall survival (OS). RESULTS: Five hundred thirty women were randomised to receive eribulin (n = 264) or vinorelbine (n = 266). Improvement in PFS was observed with eribulin compared with vinorelbine (hazard ratio [HR]: 0.80, 95% confidence interval [CI]: 0.65-0.98, P = 0.036); median PFS was 2.8 months in both treatment arms. The median OS was 13.4 months with eribulin and 12.5 months with vinorelbine (HR: 1.03, 95% CI: 0.80-1.31, P = 0.838). The ORR was 30.7% (95% CI: 25.2%-36.6%) with eribulin and 16.9% (95% CI: 12.6%-22.0%) with vinorelbine (P < 0.001). Treatment-emergent adverse events leading to treatment discontinuation were less frequent with eribulin (7.2%) than with vinorelbine (14.0%). CONCLUSIONS: Eribulin achieved statistically significantly superior PFS (and response rate) compared with vinorelbine in previously treated women with locally recurrent or MBC. Eribulin appeared to be better tolerated than vinorelbine, with no new safety signals observed. TRIAL REGISTRATION: National Institutes of Health ClinicalTrials.gov registry, NCT02225470. Registered 05 August 2014- Retrospectively registered. https://clinicaltrials.gov/ct2/show/NCT02225470?term=NCT02225470&rank=1.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Yuan P, Hu X, Sun T, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. Eur J Cancer. 2019. PMID: 30928806. doi:10.1016/j.ejca.2019.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。